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In October 2015, a new case of Ebola virus disease in Guin-
ea was detected. Case investigation, serology, and whole-
genome sequencing indicated possible transmission of the 
virus from an Ebola virus disease survivor to another person 
and then to the case-patient reported here. This transmission 
chain over 11 months suggests slow Ebola virus evolution.
As of May 6, 2016, a total of 28,616 Ebola virus dis-ease (EVD) cases, including 11,310 deaths, had been 
reported since December 2013, mainly from Guinea, Sierra 
Leone, and Liberia (1). Ebola virus often persists in im-
mune-privileged sites of survivors, resulting in detectable 
virus in semen and other body fluids (2–5). Because sperm 
can shed Ebola virus (EBOV) for <10 months after illness 
onset, exposure to semen of infected survivors can lead to 
EVD flare-ups (5–8). In utero transmission of EBOV from 
an asymptomatic mother is also possible (9).
A powerful tool for following the course of an epi-
demic of diseases for which human-to-human transmission 
is prevalent is molecular typing. In Guinea, an in-field se-
quencing facility was deployed in May 2015, and by Sep-
tember, when the outbreak was fading, EBOV genomes 
were available for ≈90% of new EVD cases (10). We report 
epidemiologic and molecular evidence of an unusual chain 
of EBOV transmission. This chain includes an EVD survi-
vor, who recovered in December 2014; possibly his wife 
(the woman) or a third unknown person; and the woman’s 
brother, who became ill with EVD in October 2015 (the 
case-patient). 
The National Committee of Ethics in Medical Re-
search of Guinea approved use of archived diagnostic sam-
ples and corresponding patient data for this study (permit 
no. 11/CNERS/14). Written consent for publication of con-
fidential data was collected for all patients described here.
The Study
On October 8, 2015, the case-patient in Conakry, Guinea, 
became ill with fever and appetite loss. His brother-in-law, 
an EVD survivor and nurse living in the same household, 
diagnosed malaria, but the case-patient did not respond to 
malaria treatment; diarrhea, headache, and abdominal pain 
developed. Four days later, he started bleeding from the 
nose. On October 13, reverse transmission PCR (RT-PCR) 
of the case-patient’s blood was positive for EBOV (11). 
From September 2015 until confirmation of EVD for this 
case-patient, only 7 cases of EVD in Guinea had been report-
ed, all part of the same chain of transmission. Of these cases, 
virus was not sequenced for 2 because the epidemiologic link 
was not clearly established. Because the case-patient we re-
port did not have any link with ongoing EVD clusters inves-
tigated in Guinea or Sierra Leone, the most likely source of 
infection was the survivor. Because EBOV is shed in survi-
vors’ semen long after recovery (7), within-marriage sexual 
transmission from the survivor to the woman was inferred. 
Blood, urine, and buccal swab samples from the cou-
ple were collected, together with semen and vaginal swab 
samples; all were negative for EBOV by RT-PCR. Blood, 
urine, buccal, and vaginal swab samples were processed as 
in (11) and seminal fluid samples as in (10). The woman’s 
serum was positive according to IgG and IgM ELISA test-
ing (both titers >1:6,400); the survivor’s serum was posi-
tive for IgG only (titer >1:3,200) (12). Serum from the only 
other household member, the couple’s 11-year-old daugh-
ter, was negative for IgG and IgM. Although the woman’s 
IgM titer was suggestive of a recent EBOV infection, she 
reported having had only a mild 2-day clinical episode back 
in early September, characterized by myalgia, joint pain, 
and low-back pain (Figure 1). The couple declared that 
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they had had no sexual intercourse for 6 months after the 
survivor was discharged from an Ebola treatment unit. 
The near full-genome sequence of virus from the case-
patient, obtained as previously described (10), was avail-
able on October 15, 2015. Phylogenetic analysis demon-
strated that it belonged to the GN1 lineage rather than the 
SL3 lineage that was circulating in Conakry during the 
second half of 2015 (Figure 2, panel A). Thus, the cases 
were probably not linked to the known ongoing chain of 
transmission in this area because sequencing of the viruses 
involved in the Guinea epidemic had been thoroughly per-
formed at this time and no GN1 lineage viruses had been 
detected in Guinea since the end of June 2015 (10). The se-
quence of the virus isolated from the case-patient, however, 
could not be closely linked to any known subclusters within 
GN1. The most closely related viruses were recovered from 
EVD patients in March 2015, but phylogenetic inference 
suggests that the new sequence had not evolved from these 
patients and instead shared a common ancestor from late 
2014 (Figure 2, panel B).
Because various samples from the survivor (including 
semen) and from the woman were negative for EBOV (Fig-
ure 1), serum collected during the survivor’s acute phase of 
EVD (November 28, 2014) was retrieved from an archived 
collection and sequenced, together with a sample from the 
person who was thought to have transmitted the infection 
to him (IPD_2163) (Figure 2, panel B). These 2 EBOV 
sequences were indistinguishable and clustered with virus 
sequences from the case-patient, differing at 6 nt sites. This 
difference over an 11-month period is smaller than expect-
ed from the estimated EBOV evolutionary rate that would 
predict 22.5 (95% CI 13–33) mutations (Figure 2, panel C).
Several lines of evidence converge toward an unusual 
chain of transmission. Most likely, the first patient sexually 
transmitted EBOV to the woman 9 months after his onset 
of EVD in 2014, and then either the woman (with a recent 
history of undetected EBOV infection) or a third unknown 
person transmitted the virus to the case-patient. After 10.5 
months, virus from the case-patient differed from that of 
the survivor by only 6 nt substitutions. These substitutions 
were not present in other virus sequences from the GN1 
lineage, demonstrating that the isolates are closely related 
to each other and more distantly related to others.
The number of substitutions between the 2 genomes 
was 3.7 times lower than would be expected after human-
to-human transmission and may indicate virus persistence 
in 1 person. This hypothesis is in line with reduced evolu-
tionary rates of persistent EBOV reported in Liberia and 
Sierra Leone (7,8,13).
Serologic data revealed that the woman had recently 
been infected with EBOV. However, none of her samples 
(i.e., blood, urine, and vaginal swab) were positive for EBOV 
by RT-PCR; therefore, no genomic data were available.
The serial interval between the case-patient’s onset 
of symptoms and that of the woman (≈30 days) is longer 
than the usual EVD maximum incubation period (21 days). 
Therefore, the woman may have more recently experienced 
mild or asymptomatic infection.
We have no molecular evidence that the woman 
was part of this chain of transmission; it is plausible that 
a third unknown person infected the case-patient. It was 
impossible to investigate potential direct male-to-male 
sexual transmission.
Conclusions
A likely explanation of our observations, integrating genom-
ic, serologic, and epidemiologic data, is that within-marriage 
sexual transmission occurred (inferred from the positive IgM 
titers of the woman) and then the woman infected her broth-
er through close contact. They all lived in the same small 
household in poor hygienic conditions; shared toilets, meals, 
and at times beds; and cared for each other. Alternatively, a 
third unknown person may have been the link in the trans-
mission from the survivor to the case-patient.
Figure 1. Timeline of the reported chain of transmission of Ebola virus involving 3 persons in Conkary, Guinea, 2014–2015. ETU, Ebola 
treatment unit; RT-PCR, reverse transcription PCR; –, negative; +, positive. 
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Interim advice with regard to sexual transmission of 
EBOV has been updated recently (14). All EVD survivors 
and their sex partners should receive condoms and coun-
seling to ensure safer sex practices. Safer sex practices 
should continue until the results of semen testing are nega-
tive twice or, if testing is unavailable, for 12 months. The 
safer sex strategy and testing could be complemented by 
new medical countermeasures that need to be assessed and 
include use of antiviral drugs, vaccination of relatives and 
sex partners of survivors, or both.
Acknowledgments
We thank Josep Jansa for stimulating discussions, and we 
thank all institutions that are part of the Global Outbreak  
Alert and Response Network (GOARN) for support to the 
Ebola outbreak response in Guinea. We also thank the GOARN 
Operational Support Team at the World Health Organization 
(WHO) headquarters, which coordinated and supported  
deployments in West Africa.
The WHO and the Institut Pasteur de Dakar financed this 
study. The work provided by the EMLab (a technical partner 
of the WHO Emerging and Dangerous Pathogens Laboratory) 
and the GOARN was conducted in the context of the projects 
EVIDENT (Ebola virus disease: correlates of protection, 
determinants of outcome, and clinical management) and 
REACTION!, which received funding from the European 
Union Horizon 2020 research and innovation program under 
grant agreement nos. 666100 and 666092, respectively, and in 
the context of service contract IFS/2011/272-372, funded by 
Directorate-General for International Cooperation  
and Development.
Dr. Keita is a medical doctor and epidemiologist. During the 
Ebola outbreak, he worked as a WHO Field Coordinator and 
Figure 2. Phylogenetic analysis of Ebola viruses. A) Maximum-
likelihood tree of 1,067 Ebola virus sequences from the West 
Africa epidemic, showing country of origin of each isolate. The 
2 lineages that circulated in Guinea in 2015 were GN1 and SL3. 
Ebola virus disease cases from Conakry, Guinea, obtained in 
the second half of 2015 (from June on) are denoted by a red dot 
on the tree branches. Box indicates 2015 isolates from the GN1 
lineage. B) Expanded view of the GN1 lineage from panel A. 
Blue dots indicate sequences from cases described in this article  
(survivor, IPD_2197; person who infected the survivor, IPD_2163; 
case-patient, CON12930); red dots indicate other cases from 
2015. Sequences can be found under the European Nucleotide 
Archive study no. ERP011834 (http://www.ebi.ac.uk/ena/data/
view/PRJEB10571). Scale bar indicates nucleotide substitutions 
per siite. C) Root-to-tip plot for the entire GN1 lineage; colors 
match those in panel B. A linear model line of best fit is shown; 
gray shading represents the confidence level around the 
regression line as SE.
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